Butyrolactone: more than a kinase inhibitor?

Cell Cycle. Mar-Apr 2002;1(2):117-8. doi: 10.4161/cc.1.2.114.

Authors

Joanna Bloom¹, Michele Pagano

Affiliation

¹ Department of Pathology and NYU Cancer Center; MSB599, New York University School of Medicine; 550 First Avenue; New York, New York 10016, USA.

PMID: 12429918
DOI: 10.4161/cc.1.2.114

No abstract available

Publication types

Review
Comment

MeSH terms

Animals
Butyrophenones / pharmacology*
CDC2 Protein Kinase / antagonists & inhibitors
CDC2-CDC28 Kinases*
Cell Cycle
Cyclin-Dependent Kinase 2
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinases / antagonists & inhibitors*
Cyclins / metabolism*
DNA Damage*
Peptide Synthases / metabolism
Protein-Serine-Threonine Kinases / antagonists & inhibitors
SKP Cullin F-Box Protein Ligases
Signal Transduction*
Tumor Suppressor Protein p53 / metabolism

Substances

Butyrophenones
Cyclin-Dependent Kinase Inhibitor p21
Cyclins
Tumor Suppressor Protein p53
SKP Cullin F-Box Protein Ligases
Protein-Serine-Threonine Kinases
CDC2 Protein Kinase
CDC2-CDC28 Kinases
Cyclin-Dependent Kinase 2
Cyclin-Dependent Kinases
Peptide Synthases